AVANOS MEDICAL (AVNS) Competitors $12.35 -0.03 (-0.24%) As of 03:30 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVNS vs. NVCR, LMAT, EYE, ENOV, CNMD, TNDM, SSII, CDRE, AORT, and LQDAShould you be buying AVANOS MEDICAL stock or one of its competitors? The main competitors of AVANOS MEDICAL include NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Tandem Diabetes Care (TNDM), SS Innovations International (SSII), Cadre (CDRE), Artivion (AORT), and Liquidia Technologies (LQDA). These companies are all part of the "medical equipment" industry. AVANOS MEDICAL vs. Its Competitors NovoCure LeMaitre Vascular National Vision Enovis CONMED Tandem Diabetes Care SS Innovations International Cadre Artivion Liquidia Technologies NovoCure (NASDAQ:NVCR) and AVANOS MEDICAL (NYSE:AVNS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings. Which has more risk and volatility, NVCR or AVNS? NovoCure has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, AVANOS MEDICAL has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Do analysts prefer NVCR or AVNS? NovoCure currently has a consensus target price of $32.83, suggesting a potential upside of 85.45%. Given NovoCure's stronger consensus rating and higher probable upside, equities analysts clearly believe NovoCure is more favorable than AVANOS MEDICAL.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovoCure 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67AVANOS MEDICAL 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to NVCR or AVNS? In the previous week, NovoCure had 10 more articles in the media than AVANOS MEDICAL. MarketBeat recorded 10 mentions for NovoCure and 0 mentions for AVANOS MEDICAL. AVANOS MEDICAL's average media sentiment score of 1.84 beat NovoCure's score of 0.39 indicating that AVANOS MEDICAL is being referred to more favorably in the news media. Company Overall Sentiment NovoCure Neutral AVANOS MEDICAL Very Positive Which has preferable earnings & valuation, NVCR or AVNS? NovoCure has higher earnings, but lower revenue than AVANOS MEDICAL. NovoCure is trading at a lower price-to-earnings ratio than AVANOS MEDICAL, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovoCure$605.22M3.26-$168.63M-$1.51-11.73AVANOS MEDICAL$687.80M0.83-$392.10M-$8.37-1.48 Do insiders & institutionals have more ownership in NVCR or AVNS? 84.6% of NovoCure shares are held by institutional investors. Comparatively, 95.2% of AVANOS MEDICAL shares are held by institutional investors. 5.5% of NovoCure shares are held by insiders. Comparatively, 2.6% of AVANOS MEDICAL shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is NVCR or AVNS more profitable? NovoCure has a net margin of -26.41% compared to AVANOS MEDICAL's net margin of -55.80%. AVANOS MEDICAL's return on equity of 6.26% beat NovoCure's return on equity.Company Net Margins Return on Equity Return on Assets NovoCure-26.41% -45.46% -13.34% AVANOS MEDICAL -55.80%6.26%4.63% SummaryNovoCure beats AVANOS MEDICAL on 9 of the 16 factors compared between the two stocks. Get AVANOS MEDICAL News Delivered to You Automatically Sign up to receive the latest news and ratings for AVNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVNS vs. The Competition Export to ExcelMetricAVANOS MEDICALMED INSTRUMENTS IndustryMedical SectorNYSE ExchangeMarket Cap$572.50M$6.92B$5.54B$20.57BDividend YieldN/A1.23%5.38%3.75%P/E Ratio-1.4826.6327.3828.04Price / Sales0.8399.70422.3138.39Price / Cash1.0420.9736.6322.31Price / Book0.684.748.084.59Net Income-$392.10M$173.18M$3.16B$985.44M7 Day Performance1.69%1.52%2.12%2.91%1 Month Performance-0.60%0.14%4.43%5.47%1 Year Performance-36.41%28.37%35.62%14.61% AVANOS MEDICAL Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVNSAVANOS MEDICAL3.4587 of 5 stars$12.35-0.2%N/A-36.6%$572.50M$687.80M-1.482,227Positive NewsNVCRNovoCure3.6962 of 5 stars$16.61-0.5%$32.83+97.7%+6.4%$1.86B$605.22M-11.001,488LMATLeMaitre Vascular2.5822 of 5 stars$83.38+2.0%$97.83+17.3%+3.3%$1.85B$219.86M42.11490EYENational Vision2.6309 of 5 stars$22.69-0.8%$18.67-17.7%+93.6%$1.81B$1.82B-68.7613,411ENOVEnovis4.0598 of 5 stars$30.01-0.3%$58.00+93.3%-25.2%$1.72B$2.11B-2.157,367CNMDCONMED4.7232 of 5 stars$51.72-0.9%$62.20+20.3%-19.1%$1.61B$1.31B13.613,900News CoverageTNDMTandem Diabetes Care4.3059 of 5 stars$20.22flat$33.43+65.3%-56.4%$1.35B$940.20M-7.272,650Positive NewsSSIISS Innovations InternationalN/A$5.65-18.4%N/AN/A$1.34B$22.13M0.004News CoverageCDRECadre3.6823 of 5 stars$32.76-0.3%$37.50+14.5%-5.7%$1.34B$567.56M34.482,284AORTArtivion2.539 of 5 stars$30.84+1.9%$32.00+3.8%+20.6%$1.29B$388.54M-61.671,600LQDALiquidia Technologies3.3754 of 5 stars$13.26+0.7%$26.89+102.8%+1.9%$1.13B$14M-8.3950 Related Companies and Tools Related Companies NovoCure Competitors LeMaitre Vascular Competitors National Vision Competitors Enovis Competitors CONMED Competitors Tandem Diabetes Care Competitors SS Innovations International Competitors Cadre Competitors Artivion Competitors Liquidia Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AVNS) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVANOS MEDICAL, INC. Please log in to your account or sign up in order to add this asset to your watchlist. Share AVANOS MEDICAL With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
